---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-311072"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:22:56.771309+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# JNJ completes $16.6B acquisition of Abiomed; $380/sh + CVR up to $35/sh

## Summary
- Tender offer expired with ~57.1% of shares tendered; all conditions satisfied.
- Abiomed will operate as a standalone business within JNJ's MedTech segment.
- Transaction expected slightly dilutive to neutral to adjusted EPS in year one, accretive by $0.05 in 2024.
- Abiomed common stock ceased trading on NASDAQ upon completion.

## SEC filing metadata
- accession: 0001193125-22-311072
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/0001193125-22-311072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/d428734d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-311072
- JSON: https://secwatch.observer/filing/0001193125-22-311072.json
- Plain text: https://secwatch.observer/filing/0001193125-22-311072.txt

## Key facts
- M&A Transactions
  JOHNSON & JOHNSON completed an acquisition involving ABIOMED for approximately $17.1 billion (closed 2022-12-22).
  - Action: acquisition
  - Counterparty: ABIOMED
  - Consideration: approximately $17.1 billion
  - Closing: 2022-12-22
  source text: in each case, multiplied by the number of Shares underlying such ABIOMED RSU. The aggregate amount paid by Purchaser in the Offer and the Merger for the Shares was approximately $17.1 billion, excluding related fees and expenses. Johnson & Johnson and Purchaser funded the acquisition of the Shares in the Offer and the Merger through a combination of Johnson &
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/0001193125-22-311072-index.htm
- Material Agreements
  JOHNSON & JOHNSON entered into Contingent Value Rights Agreement with American Stock Transfer & Trust Company, LLC valued at Each CVR represents the non-tradeable contractual right to receive contingent cash payments of up to (effective 2022-12-22).
  - Action: entry
  - Counterparty: American Stock Transfer & Trust Company, LLC
  - Value: Each CVR represents the non-tradeable contractual right to receive contingent cash payments of up to
  - Effective: 2022-12-22
  source text: on December 22, 2022, Johnson & Johnson and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, entered into a Contingent Value Rights Agreement (the “ CVR Agreement ”) governing the terms of the CVRs (as defined below) issued pursuant to the Offer and the Merger (as defined below).
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/0001193125-22-311072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.